These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
523 related articles for article (PubMed ID: 29468965)
1. Versatility of Cancer Associated Fibroblasts: Commendable Targets for Anti-tumor Therapy. Khan GJ; Sun L; Khan S; Yuan S; Nongyue H Curr Drug Targets; 2018; 19(13):1573-1588. PubMed ID: 29468965 [TBL] [Abstract][Full Text] [Related]
2. Broadening Drug Design and Targets to Tumor Microenvironment? Cancer-Associated Fibroblast Marker Expression in Cancers and Relevance for Survival Outcomes. Dzobo K; Dandara C OMICS; 2020 Jun; 24(6):340-351. PubMed ID: 32496971 [TBL] [Abstract][Full Text] [Related]
3. Nano-Strategies to Target Breast Cancer-Associated Fibroblasts: Rearranging the Tumor Microenvironment to Achieve Antitumor Efficacy. Truffi M; Mazzucchelli S; Bonizzi A; Sorrentino L; Allevi R; Vanna R; Morasso C; Corsi F Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30871158 [TBL] [Abstract][Full Text] [Related]
4. Architecture of Cancer-Associated Fibroblasts in Tumor Microenvironment: Mapping Their Origins, Heterogeneity, and Role in Cancer Therapy Resistance. Dzobo K; Dandara C OMICS; 2020 Jun; 24(6):314-339. PubMed ID: 32496970 [TBL] [Abstract][Full Text] [Related]
5. Repurposed drug screen identifies cardiac glycosides as inhibitors of TGF-β-induced cancer-associated fibroblast differentiation. Coleman DT; Gray AL; Stephens CA; Scott ML; Cardelli JA Oncotarget; 2016 May; 7(22):32200-9. PubMed ID: 27058757 [TBL] [Abstract][Full Text] [Related]
6. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mao X; Xu J; Wang W; Liang C; Hua J; Liu J; Zhang B; Meng Q; Yu X; Shi S Mol Cancer; 2021 Oct; 20(1):131. PubMed ID: 34635121 [TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of cancer-associated fibroblasts: Opportunities for precision medicine. Kanzaki R; Pietras K Cancer Sci; 2020 Aug; 111(8):2708-2717. PubMed ID: 32573845 [TBL] [Abstract][Full Text] [Related]
8. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Fiori ME; Di Franco S; Villanova L; Bianca P; Stassi G; De Maria R Mol Cancer; 2019 Mar; 18(1):70. PubMed ID: 30927908 [TBL] [Abstract][Full Text] [Related]
9. Cancer-Associated Fibroblasts in Conversation with Tumor Cells in Endometrial Cancers: A Partner in Crime. Pradip D; Jennifer A; Nandini D Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502029 [TBL] [Abstract][Full Text] [Related]
10. Activation of mutated TRPA1 ion channel by resveratrol in human prostate cancer associated fibroblasts (CAF). Vancauwenberghe E; Noyer L; Derouiche S; Lemonnier L; Gosset P; Sadofsky LR; Mariot P; Warnier M; Bokhobza A; Slomianny C; Mauroy B; Bonnal JL; Dewailly E; Delcourt P; Allart L; Desruelles E; Prevarskaya N; Roudbaraki M Mol Carcinog; 2017 Aug; 56(8):1851-1867. PubMed ID: 28277613 [TBL] [Abstract][Full Text] [Related]
11. miRNAs Delivery for Cancer-associated Fibroblasts' Activation and Drug Resistance in Cancer Microenvironment. Anajafi S; Paryan M; Khoshnazar A; Soleimani M; Mohammadi-Yeganeh S Endocr Metab Immune Disord Drug Targets; 2024; 24(3):333-347. PubMed ID: 37612874 [TBL] [Abstract][Full Text] [Related]
12. In search of definitions: Cancer-associated fibroblasts and their markers. Nurmik M; Ullmann P; Rodriguez F; Haan S; Letellier E Int J Cancer; 2020 Feb; 146(4):895-905. PubMed ID: 30734283 [TBL] [Abstract][Full Text] [Related]
13. A centralized communication network: Recent insights into the role of the cancer associated fibroblast in the development of drug resistance in tumors. Leask A Semin Cell Dev Biol; 2020 May; 101():111-114. PubMed ID: 31708414 [TBL] [Abstract][Full Text] [Related]
14. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer. Takai K; Le A; Weaver VM; Werb Z Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881 [TBL] [Abstract][Full Text] [Related]
15. Suppression of TGFβ-mediated conversion of endothelial cells and fibroblasts into cancer associated (myo)fibroblasts via HDAC inhibition. Kim DJ; Dunleavey JM; Xiao L; Ollila DW; Troester MA; Otey CA; Li W; Barker TH; Dudley AC Br J Cancer; 2018 May; 118(10):1359-1368. PubMed ID: 29695769 [TBL] [Abstract][Full Text] [Related]
16. Cancer associated fibroblast mediated chemoresistance: A paradigm shift in understanding the mechanism of tumor progression. Jena BC; Das CK; Bharadwaj D; Mandal M Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188416. PubMed ID: 32822826 [TBL] [Abstract][Full Text] [Related]
18. DT-13 inhibits breast cancer cell migration via non-muscle myosin II-A regulation in tumor microenvironment synchronized adaptations. Gao Y; Khan GJ; Wei X; Zhai KF; Sun L; Yuan S Clin Transl Oncol; 2020 Sep; 22(9):1591-1602. PubMed ID: 32056128 [TBL] [Abstract][Full Text] [Related]
19. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic. Dzobo K OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591 [TBL] [Abstract][Full Text] [Related]
20. The transformation of cancer-associated fibroblasts: Current perspectives on the role of TGF-β in CAF mediated tumor progression and therapeutic resistance. Chandra Jena B; Sarkar S; Rout L; Mandal M Cancer Lett; 2021 Nov; 520():222-232. PubMed ID: 34363903 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]